| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Nuclear Medicine, University of Ulm, Ulm, Germany
Correspondence: For correspondence or reprints contact: Florian Moog, MD, Department of Nuclear Medicine, Ludwig-Maximilian-Universität München, Marchionini-Str. 15, D-81366 München, Germany.
ABSTRACT
Recent studies indicated that 18F-fluorodeoxyglucose (FDG) PET may be more accurate than CT in staging nodal and extranodal malignant lymphoma. The objective of this study was to compare conventional bone scintigraphy as an established skeletal staging procedure with PET using FDG in the detection of osseous involvement in malignant lymphoma. Methods: Whole-body PET-based staging studies of 56 consecutive patients with proven Hodgkin's disease (n = 34) or non-Hodgkin's lymphoma (n = 22) were compared with the results of bone scintigraphy. Positive PET or bone scintigraphic findings were confirmed, if possible, by biopsy, MRI, CT or radiographic investigations. Results: Of the 56 patients studied, 12 were found to have skeletal involvement on both studies (PET, 30 regions; bone scintigraphy, 20 regions). Findings were confirmed in all 12 patients. FDG PET detected an additional 12 involved regions in 5 patients. This was subsequently verified in 3 patients, although the other 2 cases remained unresolved. Conversely, bone scintigraphy revealed five abnormalities compatible with lymphoma in 5 patients. Three of these lesions were found to be erroneous; final evaluation of the remaining two findings was not possible. Conclusion: FDG PET is suitable for identifying osseous involvement in malignant lymphoma with a high positive predictive value and is thereby more sensitive and specific than bone scintigraphy.
Key Words: lymphoma • 18F-fluorodeoxyglucose • bone scintigraphy • skeletal involvement • staging
This article has been cited by other articles:
|
|
 |
|
  Y. Nakamoto, C. Cohade, M. Tatsumi, D. Hammoud, and R. L. Wahl CT Appearance of Bone Metastases Detected with FDG PET as Part of the Same PET/CT Examination Radiology, November 1, 2005; 237(2): 627 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Even-Sapir Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities J. Nucl. Med., August 1, 2005; 46(8): 1356 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Pakos, A. D. Fotopoulos, and J. P.A. Ioannidis 18F-FDG PET for Evaluation of Bone Marrow Infiltration in Staging of Lymphoma: A Meta-Analysis J. Nucl. Med., June 1, 2005; 46(6): 958 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Metser, O. Goor, H. Lerman, E. Naparstek, and E. Even-Sapir PET-CT of Extranodal Lymphoma Am. J. Roentgenol., June 1, 2004; 182(6): 1579 - 1586. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Rohren, T. G. Turkington, and R. E. Coleman Clinical Applications of PET in Oncology Radiology, May 1, 2004; 231(2): 305 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Even-Sapir, U. Metser, G. Flusser, L. Zuriel, Y. Kollender, H. Lerman, G. Lievshitz, I. Ron, and E. Mishani Assessment of Malignant Skeletal Disease: Initial Experience with 18F-Fluoride PET/CT and Comparison Between 18F-Fluoride PET and 18F-Fluoride PET/CT J. Nucl. Med., February 1, 2004; 45(2): 272 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Metser, H. Lerman, A. Blank, G. Lievshitz, F. Bokstein, and E. Even-Sapir Malignant Involvement of the Spine: Assessment by 18F-FDG PET/CT J. Nucl. Med., February 1, 2004; 45(2): 279 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Meyer, R. F. Ambinder, and S. Stroobants Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice Hematology, January 1, 2004; 2004(1): 184 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Friedberg and V. Chengazi PET Scans in the Staging of Lymphoma: Current Status Oncologist, October 1, 2003; 8(5): 438 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yoshioka, K. Yamaguchi, K. Kubota, T. Saginoya, T. Yamazaki, T. Ido, G. Yamaura, H. Takahashi, H. Fukuda, and R. Kanamaru Evaluation of 18F-FDG PET in Patients with Advanced, Metastatic, or Recurrent Gastric Cancer J. Nucl. Med., May 1, 2003; 44(5): 690 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Israel, M. Mekel, R. Bar-Shalom, R. Epelbaum, N. Hermony, N. Haim, E. J. Dann, A. Frenkel, M. Ben-Arush, and D. Gaitini Bone Lymphoma: 67Ga Scintigraphy and CT for Prediction of Outcome After Treatment J. Nucl. Med., October 1, 2002; 43(10): 1295 - 1303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps A Tabulated Summary of the FDG PET Literature J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
